In vitro: In MDA-MB-453 cells, BLU9931 potently inhibits phosphorylation of FGFR4 signaling pathway. BLU9931 inhibits proliferation of HCC cell lines that express an intact FGFR4 signaling complex, such as Hep 3B, HUH-7, and JHH-7 cell lines, with EC50 of <1 μM. BLU9931 also inhibits proliferation in PDX-derived cell lines with an intact FGFR4 signaling pathway.
In vivo: In mice bearing the FGF19-amplified Hep 3B liver tumors, BLU9931 (300 mg/kg, p.o.) leads to tumor regression and prevents this weight loss induced by tumors. In mice bearing the FGF19-overexpressing PDX-derived LIXC012 xenografts, treatment with BLU9931 (300 mg/kg, p.o.) also leads to tumor regression.
Cell Experiment | |
---|---|
Cell lines | Hep 3B, HUH-7, JHH-7, PLC/PRF/5, SK-HEP-1, SNU-182, SNU-387, SNU-398, SNU-423, SNU-449, SNU-878 cells |
Preparation method | Established and PDX-derived HCC cell lines are seeded in 96-well plates in respective growth media, allowed to attach overnight, and treated with a dilution series of test compounds for two cell-doubling times. Cell viability is determined by CellTiter-Glo, and results represented as background-subtracted relative light units normalized to a DMSO-treated control. Relative EC50 values are determined at 50% inhibition between the top and bottom plateau of the dose–response curve. |
Concentrations | ~10 μM |
Incubation time | 72-120 hours |
Animal Experiment | |
---|---|
Animal models | Mice bearing LIXC012 tumors |
Formulation | 0.5% carboxymethylcellulose/1% Tween 80 as a suspension |
Dosages | ~300 mg/kg |
Administration | p.o. |
Molecular Weight | 509.38 |
Formula | C26H22Cl2N4O3 |
CAS Number | 1538604-68-0 |
Solubility (25°C) | 4 mg/mL warmed in DMSO |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related FGFR Products |
---|
LY-3076226
LY-3076226 is an antibody drug coupling (ADC) with a cleavable linker targeting FGFR2. |
Aprutumab ixadotin
Aprutumab ixadotin is an antibody drug coupling (ADC) with a non-cleavable linker that targets FGFR2. |
Gunagratinib
Gunagratinib is an orally active, potent, selective, and irreversible fibroblast growth factor receptor (pan-FGFR) inhibitor for use in cancer research. |
SAR-442501
SAR-442501 is a novel anti-FGFR3 monoclonal antibody for studies related to achondroplasia (ACH). |
TYRA-200
TYRA-200 is an FGFR1/2/3 (FGFR2 mutation) inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.